News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sunovion Pharmaceuticals Inc. Presents Data at CHEST 2013 from a One-year, Large Simple Safety Study of BROVANA® (arformoterol tartrate) Inhalation Solution


10/29/2013 7:57:49 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Sunovion Pharmaceuticals Inc. (Sunovion) today announced results from a one-year, non-inferiority clinical trial, which showed that patients with moderate to severe chronic obstructive pulmonary disease (COPD) treated with BROVANA® (arformoterol tartrate) Inhalation Solution experienced no increased risk of serious respiratory events, including respiratory death or COPD exacerbation-related hospitalizations, irrespective of smoking status, age or disease severity.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES